Investigating Opioid Peptides: AAV Vector-Delivered Fluorescence Sensors for Studying Opioid Dynamics

In a recent study, researchers have developed a new class of genetically encoded fluorescence sensors to study the dynamics of opioid peptides in the brain. These sensors, delivered via adeno-associated virus (AAV) vectors, represent a novel approach to investigating opioid signaling. The sensors, termed κLight, δLight, and µLight, are based on kappa, delta, and mu opioid receptors, respectively. The research team conducted extensive characterization of the pharmacological profiles of these sensors in mammalian cells and dissociated neurons, providing new insights into the mechanisms of opioid signaling.

The κLight sensor enabled the identification of electrical stimulation parameters that trigger endogenous opioid release, allowing researchers to map the spatiotemporal dynamics of dynorphin volume transmission in brain slices. Additionally, in vivo studies in mice demonstrated the sensors’ effectiveness in detecting optogenetically driven opioid release. The findings also revealed differential opioid release dynamics in response to conditions associated with fear and reward.

This study marks a significant advancement in understanding the spatiotemporal dynamics of opioid signaling within the brain. The AAV vector design and delivery of these sensors provide a powerful toolset for high-resolution tracking of opioid peptides, offering potential applications in research areas related to pain, stress, reward, and addiction.

Notably, the vector element used in this research has been included in PackGene’s database. Additionally, PackGene’s online piVector designer tool offers free vector design and access to the sequences for vector elements used in this research, providing valuable resources for further exploration and application in neuroscience.

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Related Services